Beatrice Righi, Salma R Ali, Jillian Bryce, Jeremy W Tomlinson, Walter Bonfig, Federico Baronio, Eduardo C Costa, Guilherme Guaragna-Filho, Guy T'Sjoen, Martine Cools, Renata Markosyan, Tania A S S Bachega, Mirela C Miranda, Violeta Iotova, Henrik Falhammar, Filippo Ceccato, Marianna R Stancampiano, Gianni Russo, Eleni Daniel, Richard J Auchus, Richard J Ross, S Faisal Ahmed
PURPOSE: To study the current practice for assessing comorbidity in adults with 21-hydroxylase CAH and to assess the prevalence of comorbidity in these adults. METHODS: A structured questionnaire was sent to 46 expert centres managing adults with CAH. Information collected included current therapy and surveillance practice with a particular focus on osteoporosis/osteopaenia, hyperlipidaemia, type 2 diabetes/hyperinsulinaemia, hypertension, CV disease, obesity. RESULTS: Of the 31 (67%) centres from 15 countries that completed the survey, 30 (97%) screened for hypertension by measuring blood pressure, 30 (97%) screened for obesity, 26 (84%) screened for abnormal glucose homoeostasis mainly by using Hb1Ac (73%), 25 (81%) screened for osteoporosis mainly by DXA (92%), 20 (65%) screened for hyperlipidaemia and 6 (19%) screened for additional CV disease...
March 1, 2023: Endocrine